Model Probabilities: Cost-Effectiveness of a COPD Diagnostic Test

5.5 KB of model-based cost-utility analysis results evaluating the Biofire Film Array Respiratory Panel RP 2.1+ test for COPD patients. The data, authored by Raymond Oppong and last updated in April 2026, indicates a 70% chance the test is cost-effective and could generate annual savings between £118 million and £18.6 billion. The analysis includes two approaches for accounting for antimicrobial resistance costs.

Use Cases

• Validate cost-effectiveness model outputs based on the reported £2762.40 cost difference and 0.03 QALY gain.
• Analyze the impact of antimicrobial resistance accounting methods on economic evaluations.
• Benchmark potential healthcare savings based on the reported £118 million to £18.6 billion annual range.
• Assess the probability of cost-effectiveness for a diagnostic intervention based on the reported 70% likelihood.

Strengths

• Model parameters were informed by a targeted literature review and expert opinions.
• Analysis adopts two distinct approaches to account for antimicrobial resistance costs.
• The dataset is openly licensed under CC-BY-4.0.

Limitations

• Row count and column-level documentation are unknown, requiring manual inspection after download.
• The 5.5 KB file size suggests a very limited scope, likely containing summary outputs rather than raw or granular data.

Provenance

Source

figshare, authored by Raymond Oppong.

Collection Method

Model-based cost-utility analysis informed by literature review and expert opinion.

Time Range

Model horizon of 40 years.

Freshness

Last updated 2026-04-27 17:26:50; freshness should be verified.

Geography

null